A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer

ID Number 14-1031

Principal Investigator(s)
Matthew Galsky

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to look at the effects, good or bad, of an experimental drug called MPDL3280A on you and your bladder cancer. An experimental drug is one that is being tested and is not available to buy on the market.  MPDL3280A is an antibody (a protein produced by the body's immune system) that affects the immune system by blocking the programmed death−ligand 1 (PD-L1) pathway. The PD-L1 pathway is involved in regulating the body’s natural immune response, but tumors can take advantage of this regulation to partially resist or evade the immune system. By blocking the PDL1 pathway, MPDL3280A may help your immune system stop or reverse the growth of tumors.

Contact Information
(212) 824-7309

Recruiting Patients: No